Changes in Hong Kong stocks | Kingsley Biotech (01548) rose more than 12%, the AI pharmaceutical industry trend is clear, demand for wet experiments is expected to expand at an accelerated pace

The Zhitong Finance App learned that Kingsley Biotech (01548) rose by more than 12%. As of press release, it had risen 12.06% to HK$36.98, with a turnover of HK$1,952 billion.

According to the news, according to the latest developments published on Anthropic's official website, the company's life science team has established in-depth research cooperation with six institutions and acquired Mithril Medicine, a biotechnology company operated by a single person, to directly carry out drug research and development. It is worth noting that in the face of the definitive growth track of AI pharmaceuticals, MNC has been entering the market intensively since 2024, and will push the layout to a new climax in 2026.

Guojin Securities pointed out that the AI pharmaceutical market space is broad, accelerating the expansion of demand for wet experiments. According to reports, in September of this year, Kingsley Biotech announced that it had reached a cooperation with Lilly TuneLab, Eli Lilly's AIDD collaboration platform. According to the agreement, the company will provide wet testing services to TuneLab participating companies to help them quickly generate experimental data, transform AI predictions into biological verification data, and accelerate the evaluation of drug candidates.